Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exemestane + lenvatinib
- Development stage
- Unknown
- Lead developer
- Exeliom Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EXL1 is a combination therapy consisting of the aromatase inhibitor **exemestane** and the multikinase inhibitor **lenvatinib**. Developed by the **Centre Hospitalier Universitaire de Lille** (CHU Lille), it is currently being evaluated in a Phase 2 clinical trial (NCT04653142) for patients with advanced non-small cell lung cancer (NSCLC) who have progressed on or are refractory to immune checkpoint inhibitor (ICI) therapy. The rationale for this combination lies in the potential synergistic effects of targeting the estrogen signaling pathway, which has been implicated in lung cancer progression and immune evasion, alongside multiple receptor tyrosine kinases (including VEGFR, FGFR, and PDGFR) involved in angiogenesis and tumor growth. This dual approach is intended to overcome resistance mechanisms in lung adenocarcinoma.
- Other names
- Exemestane and Lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CYP19A1 (Aromatase)FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)AR (Adrenergic receptors)
Beyond the preview
Go deeper on exemestane + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exemestane + lenvatinib.